American Academy of Allergy, Asthma, and Immunology Virtual Annual Meeting (AAAAI 2023)

San Antonio, Texas 24 February 2023 - 27 February 2023

Alternative treatments for rhinitis could be worth a try

29 Mar 2023 bởi

Nasal sprays containing a drug-free aqueous gel emulsion or essential oils appear to help relieve symptoms of allergic rhinitis, as shown in two studies presented at AAAAI 2023.

29 Mar 2023

Promising treatment options for chronic hives on the horizon

28 Mar 2023 bởi

Dupilumab, barzolvolimab, and remibrutinib appear to help reduce disease activity in patients with chronic spontaneous urticaria, according to the results of three studies presented at AAAAI 2023.

28 Mar 2023

Biologics lower exacerbation rates in severe asthma, allergic rhinitis

28 Mar 2023 bởi

Treatment with either omalizumab (anti-immunoglobulin E [anti-IgE]) or nonomalizumab (non-anti-IgE) biologics reduced exacerbations in patients with severe asthma and allergic rhinitis, with the benefits being more evident among those taking nonomalizumab agents, according to the CHRONICLE trial presented at AAAAI 2023.

28 Mar 2023

Oral, on-the-skin immunotherapies show promise against peanut allergy in children

27 Mar 2023 bởi

Children who are allergic to peanuts may benefit from two immunotherapies, one oral and another epicutaneous or on-the-skin, which have demonstrated safety and efficacy in separate studies presented at the recent AAAAI 2023.

27 Mar 2023

VANGUARD sets the stage for a novel biologic in HAE

27 Mar 2023 bởi

Monthly injections of the investigational biologic garadacimab substantially reduced the mean attack rate in patients with hereditary angioedema (HAE) in the phase III VANGUARD trial.

27 Mar 2023

Long-term dupilumab proven safe, effective in children with asthma

24 Mar 2023 bởi

Long-term treatment with dupilumab is well tolerated, and its efficacy in children with uncontrolled, moderate-to-severe asthma as seen in the VOYAGE study is consistent, according to the EXCURSION open-label extension study. In addition, patients who switched from placebo to dupilumab has improved rapid lung function.

24 Mar 2023

Can a cancer drug be repurposed for allergic reactions?

22 Mar 2023 bởi

A small but promising study showed that acalabrutinib, an oral BTK* inhibitor approved for B-cell malignancies**, may reduce or even prevent clinical reactivity to peanuts in peanut-allergic adults.

22 Mar 2023

Long-term OLE boosts potential of remibrutinib for CSU

20 Mar 2023 bởi

In the 52-week open-label extension (OLE) of a phase IIb study presented at AAAAI 2023, the BTK* inhibitor remibrutinib demonstrated sustained efficacy and a favourable safety profile for the treatment of chronic spontaneous urticaria (CSU).

20 Mar 2023

Lanadelumab reduces HAE attacks in children

15 Mar 2023 bởi

Treatment with lanadelumab given every 2 or 4 weeks (Q2W or Q4W dosing) reduces the frequency of attacks in patients aged 2 to <12 years with hereditary angioedema (HAE), according to the SPRING study presented at AAAAI 2023.

15 Mar 2023